AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1

Metfine IPR 500 Tablet SR

Prescription Icon
Prescription Required

Marketer

Astraea Life Sciences Pvt Ltd

Salt Composition

Metformin (500mg)

Overview Metfine IPR 500 Tablet SR

Metfine IPR 500 SR tablets manage type 2 diabetes mellitus by regulating blood glucose, mitigating the risk of severe diabetic complications. This medication also addresses Polycystic Ovary Syndrome (PCOS) in women. For optimal absorption and to minimize gastrointestinal upset, ingest Metfine IPR 500 SR with food, consistently at the same time daily. Discontinue use only under your physician's guidance. Dietary adherence and regular exercise, as prescribed, are crucial for effective diabetes management alongside this treatment. Commonly reported side effects include digestive issues (diarrhea, nausea, vomiting, gas, indigestion, abdominal discomfort), headache, fatigue, and appetite changes. Concurrent use with other antidiabetic medications, alcohol consumption, or missed meals may lead to hypoglycemia (low blood sugar); thus, regular blood glucose monitoring is essential. Prior to commencing treatment, disclose any kidney, liver, or heart conditions to your doctor. Pregnant or lactating individuals should seek medical advice before using this medication. Renal function will be assessed by your physician before prescription. Limit alcohol consumption to reduce the likelihood of adverse reactions.

Primary Ingredients of Metfine IPR 500 Tablet SR

No text provided to rephrase.

Uses of Metfine IPR 500 Tablet SR

Managing type 2 diabetes and polycystic ovary syndrome (PCOS)

Major Benefits of Metfine IPR 500 Tablet SR:

Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Metfine IPR 500 SR tablets should be administered with a meal.

Common Side effects of Metfine IPR 500 Tablet SR:

  • Diarrhea
  • Headache
  • Vomiting
  • Nausea
  • Flatulence
  • Abdominal discomfort
  • Weakness

How to use Metfine IPR 500 Tablet SR:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Metfine IPR 500 SR tablets should be administered with a meal.

How Metfine IPR 500 Tablet SR works:

Glucophage XR 500mg extended-release tablets are a biguanide-class antidiabetic drug. Their mechanism of action involves reducing hepatic glucose output, slowing intestinal glucose uptake, and enhancing insulin responsiveness.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Metfine IPR 500 Tablet SR and alcohol is not advisable due to safety concerns.

PregnancyPregnancySAFE IF PRESCRIBED

Metfine IPR 500 SR tablets are typically deemed safe for use during gestation. Preclinical trials in animals have revealed minimal or no negative consequences for fetal development; nevertheless, research involving human subjects is scant.

Breast feedingBreast feedingCAUTION

Extended-release Metfine IPR 500mg tablets require careful consideration when breastfeeding. Mothers should discontinue breastfeeding throughout treatment and until the medication is fully cleared from their system.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Metfine IPR 500 SR tablets cautiously, potentially requiring dosage modification. Consult a physician for guidance. Metfine IPR 500 SR tablets are contraindicated in individuals with severe kidney disease.

LiverLiverUNSAFE

Extended-release Metfine IPR 500mg tablets are contraindicated for individuals with hepatic impairment and should be omitted. Physician consultation is advised.

What if you forget to take Metfine IPR 500 Tablet SR :

Should you forget to take a Metfine IPR 500 Tablet SR, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Metfine IPR 500 Tablet SR

LabelValue
Type of Compound Guanidine-based hypoglycemic agents
Potential for Dependence None.
Type of Medication Medication for diabetes

FAQs on Metfine IPR 500 Tablet SR

Individuals with type 2 diabetes exhibit impaired responsiveness to endogenous insulin. Consequently, blood glucose concentrations elevate. Metfine IPR 500 Tablet SR employs multiple mechanisms to lower these elevated blood sugar levels. This medication reduces hepatic glucose production, diminishes intestinal glucose absorption postprandially, and enhances insulin sensitivity in peripheral tissues. This combined action facilitates improved glucose uptake from the bloodstream and augments the body's natural insulin response.
Metfine IPR 500 SR tablets have demonstrated weight reduction in overweight and obese patients. This weight loss effect may also be observed in overweight and obese individuals predisposed to diabetes. Furthermore, individuals with insulin sensitivity or resistance may experience weight loss. However, self-initiation of this medication for weight management is discouraged. Consult a physician before use.
Metfine IPR 500 Tablet SR is an initial treatment option for individuals with elevated blood glucose. This medication manages blood sugar by enhancing the body's insulin sensitivity, reducing hepatic glucose production, and limiting intestinal glucose absorption. Differing from other oral hypoglycemics, Metfine IPR 500 Tablet SR, when used independently, infrequently leads to hypoglycemia due to its mechanism of action, which avoids excessive pancreatic insulin release. Beyond glycemic control, it also aids in weight management.
Metfine IPR 500 SR tablets typically do not induce drowsiness and are generally well-received. Infrequently, however, Metfine IPR 500 SR tablets may result in sleep disturbances or insomnia. Somnolence can be a symptom of a severe adverse reaction known as lactic acidosis, especially prevalent in individuals with impaired renal function. Consult your physician if fatigue or sleepiness develops during Metfine IPR 500 SR treatment.
Administer Metfine IPR 500 Tablet SR either during or following a meal. Avoid crushing or chewing the tablets; ingest them whole with water. For once-daily regimens, morning consumption with breakfast is recommended. Twice-daily prescriptions should be divided, one dose in the morning and the other in the evening with dinner. Three times daily, doses should be taken with breakfast, lunch, and dinner. Consuming Metfine IPR 500 Tablet SR with food mitigates potential gastrointestinal distress such as indigestion, nausea, vomiting, diarrhea, abdominal pain, and anorexia.
Individuals with type 2 diabetes either produce insufficient insulin or exhibit impaired responsiveness to their body's insulin production. This results in elevated blood glucose levels. Metfine IPR 500 Tablet SR employs a multifaceted approach to lower these elevated blood sugar levels. It reduces hepatic glucose production, diminishes intestinal glucose absorption following meals, and enhances insulin sensitivity in bodily tissues. This combined action facilitates improved glucose uptake from the bloodstream. Consequently, it improves the body's natural insulin response.
Metfine IPR 500 SR tablets have demonstrated a weight-reducing effect in overweight and obese patients. This weight loss may also be observed in overweight or obese individuals predisposed to diabetes. Furthermore, individuals with insulin resistance or sensitivity may experience similar results. However, self-medicating with this drug for weight management is inadvisable; always seek professional medical counsel.
Metfine IPR 500 SR tablets are frequently an initial treatment for hyperglycemia. This medication manages blood glucose by enhancing the body's insulin sensitivity, reducing hepatic glucose production, and minimizing intestinal glucose absorption. Differing from other oral antidiabetic agents, Metfine IPR 500 SR monotherapy infrequently leads to hypoglycemia due to its mechanism that avoids excessive pancreatic insulin release. Beyond glycemic control, this medication also aids in weight management.
Metfine IPR 500 SR tablets generally don't induce drowsiness and are typically well-received. Infrequently, however, Metfine IPR 500 SR tablets may lead to sleep disturbances or insomnia. Excessive sleepiness can signal a severe adverse reaction known as lactic acidosis, especially if renal function is impaired. Seek medical advice if fatigue or somnolence develops during Metfine IPR 500 SR treatment.
Administer Metfine IPR 500 Tablet SR during or following a meal. Avoid crushing or chewing the tablets; ingest them whole with water. For once-daily regimens, consume the tablet with breakfast. Twice-daily prescriptions should be divided, one with breakfast and one with dinner. Three times daily, distribute doses with breakfast, lunch, and dinner. Consuming Metfine IPR 500 Tablet SR with food mitigates potential gastrointestinal distress, such as indigestion, nausea, emesis, diarrhea, abdominal pain, and anorexia.
Individuals with type 2 diabetes either produce insufficient insulin or exhibit impaired responsiveness to endogenous insulin. Consequently, blood glucose levels rise. Metfine IPR 500 Tablet SR employs a multi-pronged approach to lower elevated blood sugar. This medication reduces hepatic glucose production, diminishes intestinal glucose absorption postprandially, and enhances insulin sensitivity in tissues. This combined action facilitates improved glucose uptake from the bloodstream and augments the body's natural insulin response.
Metfine IPR 500 SR tablets have demonstrated weight reduction in overweight and obese patients. This weight loss effect may also be observed, though less significantly, in overweight and obese individuals predisposed to diabetes. Furthermore, individuals with insulin resistance or sensitivity may experience weight loss. However, self-medicating with this drug for weight management is inadvisable; physician consultation is necessary.
Metfine IPR 500 SR tablets are a frontline treatment for elevated blood glucose. This medication manages blood sugar by enhancing the body's insulin sensitivity, reducing hepatic glucose production, and limiting intestinal glucose absorption. Differing from other oral hypoglycemics, Metfine IPR 500 SR, when used independently, infrequently results in hypoglycemia due to its mechanism of action, which avoids excessive pancreatic insulin release. Beyond its glycemic control benefits, this medication also aids in weight management.
Metfine IPR 500 SR tablets generally do not induce drowsiness and are typically well-received. Infrequently, though, Metfine IPR 500 SR tablets may lead to sleep disturbances or insomnia. Somnolence can be a symptom of a severe adverse reaction known as lactic acidosis, especially if renal function is impaired. Consult your physician if fatigue or sleepiness develops during Metfine IPR 500 SR treatment.
Administer Metfine IPR 500 Tablet SR during or following a meal. Avoid crushing or chewing; ingest the tablet whole with water. For once-daily prescriptions, morning ingestion with breakfast is recommended. Twice-daily regimens should involve one tablet in the morning and one in the evening with dinner. Three times daily, distribute doses across breakfast, lunch, and dinner. Consuming Metfine IPR 500 Tablet SR with food mitigates potential gastrointestinal distress, including indigestion, nausea, vomiting, diarrhea, abdominal pain, and anorexia.
Metfine IPR 500 Tablet SR
16
MRP 19
13% off